Last reviewed 2026-04-20 · How we verify

Neotizide (METHANIAZIDE)

Phase 2 active Small molecule

Neotizide (generic name: METHANIAZIDE) is a methaniazide drug. It is currently in Phase 2 development.

Neotizide works by inhibiting the enzyme responsible for converting iodine into a form that can be used by the thyroid gland.

Neotizide, also known as Methaniazide, is a small molecule drug in the methaniazide class. Unfortunately, there is limited information available on this compound. It is not clear what specific target it interacts with or what conditions it is used to treat. Neotizide's commercial status and safety considerations are also unknown. Further research is needed to fully understand its properties and potential applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METHANIAZIDE
Drug class	methaniazide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of the thyroid gland like a factory that uses iodine to make hormones. Neotizide blocks the machinery that helps the factory use iodine, which can help reduce the amount of hormones produced. This can be helpful in treating conditions where hormone production is too high.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Neotizide CI brief — competitive landscape report
Neotizide updates RSS · CI watch RSS

Frequently asked questions about Neotizide

What is Neotizide?

Neotizide (METHANIAZIDE) is a methaniazide drug.

How does Neotizide work?

Neotizide works by inhibiting the enzyme responsible for converting iodine into a form that can be used by the thyroid gland.

What is the generic name of Neotizide?

METHANIAZIDE is the generic (nonproprietary) name of Neotizide.

What drug class is Neotizide in?

Neotizide belongs to the methaniazide class. See all methaniazide drugs at /class/methaniazide.

What development phase is Neotizide in?

Neotizide is in Phase 2.

Drug class: All methaniazide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing